Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Danaher Corp., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).


The analysis of the financial ratios over several quarters reveals several important trends relating to operational efficiency and liquidity management. The inventory turnover ratio shows a gradual decline from early 2021 through mid-2023, indicating a slight reduction in how efficiently inventory is being managed. However, there is a modest improvement towards the end of 2024 before the ratio dips again slightly, suggesting some fluctuation in inventory management effectiveness.

Receivables turnover displays relative stability with minor oscillations. It peaked around mid-2022 but generally maintained a consistent range, indicating steady efficiency in collecting receivables over the observed periods. Conversely, the payables turnover ratio demonstrates an overall upward trend from the end of 2021 through 2025, which might imply quicker payment of payables or changes in supplier terms.

Working capital turnover initially shows significant volatility, with a pronounced spike in late 2021 and mid-2024, followed by sharp declines. This pattern may reflect changes in the company's operational scale or shifts in current asset and liability management strategies.

The average inventory processing period increased from 84 days in early 2021 to peaks above 100 days in parts of 2023 and 2024, signaling slower inventory movement during those times. This aligns with the decreases in inventory turnover noted earlier. After mid-2024, the period shortens, matching the temporary improvement seen in inventory turnover.

The average receivable collection period remained relatively stable, fluctuating around the mid-50-day range throughout the entire period. This consistency suggests steady credit and collection policies without significant changes impacting customer payment behavior.

The operating cycle, representing the total time from inventory acquisition to cash collection, lengthened somewhat from around 142 days in early 2021 to over 160 days in late 2023, before showing slight reductions. This aligns with earlier observations of increased average inventory and receivables periods, indicating a longer duration to convert resources into cash.

Regarding payables, the average payment period saw an increase from around 69 days early on to above 80 days by late 2021, then gradually declined to approximately 60-65 days by 2024 and remained stable afterward. This suggests a tightening of payment terms or a more prompt payment practice in recent times.

The cash conversion cycle, which measures the net time between cash outflow for payables and cash inflow from receivables and inventory, showed notable variation. It rose from about 63 days at the end of 2021 to nearly 100 days during parts of 2023, indicating increased working capital tied up in operations. Afterward, it decreased somewhat but remained elevated around the 90-day mark through 2025, suggesting ongoing challenges in cash flow optimization.

In summary, the company has experienced fluctuations in inventory management efficiency and varying payment and collection practices. The lengthened operating and cash conversion cycles over several periods reflect increased capital lock-in, which may warrant further attention for operational improvements. While receivables management remains stable, there is evidence of efforts to reduce payables periods in more recent quarters. These dynamics collectively inform the company's working capital and liquidity profile over the analyzed timeframe.


Turnover Ratios


Average No. Days


Inventory Turnover

Danaher Corp., inventory turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data (US$ in millions)
Cost of sales
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Inventory turnover = (Cost of salesQ3 2025 + Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data reflects notable fluctuations and trends in Danaher Corp.'s cost of sales, inventories, and inventory turnover over the analyzed quarterly periods.

Cost of Sales
The cost of sales exhibits a generally cyclical pattern with some periods of decline and recovery. Initially, from early 2021 through the end of 2022, the cost of sales showed an overall increasing trend, peaking around the end of 2022. Subsequently, during 2023 the cost of sales declined sharply in the first quarter, followed by fluctuations with slight recoveries and declines into early 2024. Late 2024 to mid-2025 data suggest relatively stable costs with minor quarterly variations. The fluctuations might indicate seasonal effects, changes in production volume, or shifts in pricing strategies.
Inventories
Inventory levels increased steadily from early 2021 through around mid-2022, reaching a peak before gradually declining towards the end of 2022. In early 2023, inventories rose sharply again but then showed a decreasing trend over subsequent quarters into mid-2024. From mid-2024 through mid-2025, inventories appear more stable but exhibit minor fluctuations. The inventory pattern may be influenced by supply chain dynamics, management of stock levels in response to demand forecasts, or efforts to optimize working capital.
Inventory Turnover Ratio
The inventory turnover ratio generally declined from early 2021, moving from above 4.3 down to below 3.7 by mid-2022, indicating a slower rate of inventory movement. Following this, there was a modest recovery by the end of 2022, with turnover increasing slightly above 4.1. Throughout 2023 and into 2024 and 2025, turnover ratios fluctuate mostly between 3.5 and 3.8, suggesting a moderately consistent pace of inventory turnover with minor variability. This pattern may reflect changes in sales efficiency, inventory management practices, or shifts in product demand.

Overall, the data suggest that while cost structures and inventory levels have experienced periods of volatility, inventory turnover ratios have remained relatively stable in recent quarters. The observed trends may indicate ongoing adjustments in operational strategies to balance costs with inventory management efficiency. Further investigation into external factors and internal management decisions could provide clearer insights into the drivers behind these patterns.


Receivables Turnover

Danaher Corp., receivables turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data (US$ in millions)
Sales
Trade accounts receivable, less allowance for doubtful accounts
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Receivables turnover = (SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024) ÷ Trade accounts receivable, less allowance for doubtful accounts
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends in sales, trade accounts receivable, and receivables turnover ratios over the observed periods.

Sales
Sales exhibited variability across the quarters, with an initial upward trend reaching a peak near the end of 2021 at 8,148 million US dollars. Following this peak, a decline was observed in early 2023, with values falling below 6,000 million US dollars in some quarters, notably hitting the low of 5,624 million in September 2023. Subsequently, sales showed signs of recovery in late 2023 and throughout 2024, climbing back above 6,500 million US dollars by the last quarter of 2024. The data indicates some seasonal or cyclical fluctuations, as well as possible external factors influencing sales volatility.
Trade Accounts Receivable, Less Allowance for Doubtful Accounts
Trade receivables closely paralleled sales trends but with a somewhat smoother progression. Starting at 3,949 million US dollars in April 2021, they increased steadily, peaking around 4,918 million by December 2022. After this peak, receivables declined significantly in early 2024 to a low around 3,379 million US dollars, indicating possibly improved collection efficiency or reduced credit sales. Towards mid and late 2024, trade receivables began to increase again but did not reach previous high levels by the end of the observed period.
Receivables Turnover Ratio
The receivables turnover ratio fluctuated moderately across quarters, ranging generally between 6.09 and 7.15 times per year. Early periods showed ratios around 6.3 to 6.9, with some higher spikes such as 7.09 in October 2022 and 7.15 in June 2024. The ratio tends to decrease when trade receivables increase relative to sales, and vice versa, reflecting the efficiency in collecting receivables. The turnover ratio's slight decline in late 2023 and early 2024 corresponds with a reduction in receivables, suggesting mixed effects on collection performance or credit terms during these times.

In summary, while sales and trade receivables generally correlate as expected, their volatility suggests influences of market or operational conditions affecting demand and credit extension. The receivables turnover ratio's relative stability with some variability points to a generally consistent credit collection policy with periods of moderate efficiency changes. The recent trends toward recovery in sales and gradual rise in receivables indicate possible stabilization and improved business conditions toward the end of the data period.


Payables Turnover

Danaher Corp., payables turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data (US$ in millions)
Cost of sales
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Payables turnover = (Cost of salesQ3 2025 + Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024) ÷ Trade accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


Cost of Sales
The cost of sales demonstrates a generally fluctuating pattern with some seasonality evident over the observed quarters. From early 2021 through the end of 2022, the cost exhibits an overall increasing trend, peaking notably at the end of 2021 and again at the close of 2022. Starting in 2023, the cost of sales shows marked quarter-to-quarter variability but remains within a relatively consistent range, with slight upward adjustments toward the latter quarters of 2024 and a small decline in mid-2025. This suggests some variability in input costs or sales volume but no drastic long-term increases.
Trade Accounts Payable
Trade accounts payable show a declining trend from April 2021 through the end of 2023, decreasing from close to 2,000 million USD to under 1,800 million USD. Beginning in early 2024, accounts payable stabilize with only minor fluctuations, indicating tighter management of payables or possibly more favorable payment terms. The reduction in payables relative to previous periods may reflect strategic efforts to reduce outstanding liabilities or shifts in vendor relationships.
Payables Turnover Ratio
The payables turnover ratio exhibits variability but maintains levels generally between 4.5 and 6.1 times annually. Early 2021 ratios are moderately high, then experience a dip near the end of 2021, consistent with the peak in accounts payable observed at that time. From 2022 onwards, the ratio remains relatively steady and even improves slightly with some of the highest ratios recorded in mid to late 2024, suggesting faster payment cycles and improved liquidity management. A turnover ratio consistently above 5 suggests efficient payment practices.
Overall Insights
The combination of a rising yet variable cost of sales alongside decreasing trade payables and a stable to improving payables turnover ratio indicates an effort to optimize working capital and supplier relationships. The company appears to manage its liabilities more efficiently over time while accommodating fluctuations in cost structures. The payables turnover ratio improvements imply quicker payments or better terms, contributing positively to supplier relations and possibly creditworthiness. Seasonality effects are visible but do not obscure the overall trend toward enhanced payables management.

Working Capital Turnover

Danaher Corp., working capital turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Working capital turnover = (SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals notable fluctuations in working capital, sales, and working capital turnover ratios over the observed periods. These metrics demonstrate varying operational efficiency and sales performance across consecutive quarters.

Working Capital
Working capital values exhibit significant volatility throughout the quarters. Starting from a moderate value, there is an initial increase reaching a peak in mid-2023. Afterward, a declining trend is observed with some recovery attempts, but the values remain generally lower in later periods compared to earlier peaks. This fluctuation suggests variable short-term financial liquidity and changes in the company’s current assets and liabilities management.
Sales
Sales figures follow a relatively stable but somewhat declining pattern until the end of 2022, followed by a pronounced drop in early 2023. Subsequently, sales stabilize at a lower level with minor fluctuations. This pattern indicates possible market pressures or seasonal impacts influencing revenue generation, with some recovery signs in specific quarters but without returning to the highest levels observed previously.
Working Capital Turnover
The working capital turnover ratio demonstrates marked variability, reflecting the relationship between sales and working capital. The ratio is quite high during certain quarters, indicating efficient use of working capital to generate sales, particularly in late 2021 and mid-2024 periods. Conversely, the ratio dips significantly during some intervals, especially when working capital peaks or sales decline, implying less efficient capital usage during these times. These changes highlight shifts in operational effectiveness and capital management strategy.

Overall, the data indicate periods of both strong and weak operational performance with respect to working capital management and sales generation. The oscillations in turnover ratios underscore the dynamic interplay between asset management and market conditions, suggesting areas for potential efficiency improvements in working capital utilization.


Average Inventory Processing Period

Danaher Corp., average inventory processing period calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of the financial ratios related to inventory management over the observed periods reveals certain trends and patterns.

Inventory Turnover Ratio
The inventory turnover ratio shows a generally declining trend from April 2021 to September 2023, starting at 4.34 and reaching lows around 3.5. This decline indicates a slower rate of inventory being sold or used over time. However, there is intermittent improvement noted in late 2023 and early 2024 periods, where the ratio slightly increases to values above 3.7 and peaks at 4.15 in December 2024. Nevertheless, the ratio decreases again in the first half of 2025, stabilizing around the mid-to-high 3 range. This fluctuation suggests periodic changes in inventory efficiency and potentially varying sales or production volumes.
Average Inventory Processing Period
The average inventory processing period, measured in days, inversely correlates to the turnover ratio. It increases from a low of 84 days in April 2021 to peaks around 104 days in early to mid-2023, indicating that inventory is held longer before being sold or used. Following this peak, the processing period decreases to 88 days by December 2024, consistent with the observed increase in inventory turnover during the same timeframe. However, it then increases again through the first half of 2025, moving back toward approximately 100 days. This suggests a return to slower inventory movement or increased stockholding levels.

Overall, the data suggest fluctuating inventory management efficiency, with periods of slower turnover and longer holding times followed by brief improvements. These variations may reflect changes in demand, supply chain dynamics, or inventory strategy adjustments. Continuous monitoring and targeted management actions could help sustain optimal inventory turnover rates and minimize holding periods.


Average Receivable Collection Period

Danaher Corp., average receivable collection period calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


Receivables Turnover
The receivables turnover ratio exhibits moderate fluctuations across the observed periods, generally ranging between 6.09 and 7.15. Initially, there is a progressive increase from 6.28 to a peak of 7.09 by the end of the third quarter of 2022, suggesting improved efficiency in collecting receivables during this timeframe. However, a decline follows in the fourth quarter of 2022 to 6.4, indicating a temporary slowdown. Subsequently, the ratio stabilizes with minor variations, peaking again at 7.15 in the second quarter of 2024 before gradually descending to 6.46 by the third quarter of 2025. Overall, the data reveal a pattern of cyclical improvement and deceleration, without a clear long-term upward or downward trend.
Average Receivable Collection Period
The average collection period inversely mirrors the receivables turnover, fluctuating between 51 and 60 days over the timeframe. Initially, an improvement is observed, with collection periods decreasing from 58 days to a low of 51 days by the third quarter of 2022, implying faster collection of receivables. This is followed by a reversal where the collection period increases to 60 days in the fourth quarter of 2023, signifying slower collections. Later periods show a trend towards stabilization, maintaining around 54 days with minor variances through to the third quarter of 2025. The periodic upticks in days suggest occasional challenges in receivables management that offset earlier efficiencies.
Summary of Trends
The analysis of both ratios indicates that the company's receivables management effectiveness experiences cyclical changes rather than steady improvement or decline. Peaks in receivables turnover generally coincide with troughs in collection periods, consistent with typical financial relationships. The fluctuations point to operational or market factors influencing collection efficiency intermittently. Maintaining a collection period close to the mid-50-day range over the long term indicates a relatively consistent working capital cycle, albeit with room for further optimization during periods of higher collection days.

Operating Cycle

Danaher Corp., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The analysis of the financial indicators related to inventory, receivables, and operating cycle reveals notable trends over the observed periods.

Average Inventory Processing Period

This metric shows fluctuations throughout the periods, beginning at 84 days and rising to peak values above 100 days during several quarters (e.g., 104 days in Mar 31, 2023 and Sep 29, 2023). After reaching a maximum around 102 days in mid-2024, it notably declines to 88 days by Dec 31, 2024 before stabilizing near 99-101 days in later quarters. The general pattern suggests periods of increasing inventory holding time with intermittent reductions, indicating possible adjustments in inventory management or supply chain factors.

Average Receivable Collection Period

The receivable collection period exhibits moderate variation, starting around 58 days and gradually decreasing to a low point near 51 days in mid-2024. Following this, the collection period shows a slight upward adjustment to mid-50 days, maintaining relative stability through the most recent periods. This trend indicates consistent receivables management with some improvement in collection efficiency observed during the middle periods.

Operating Cycle

The operating cycle, reflecting the sum of inventory processing and receivables collection periods, steadily increases from 142 days to a peak of 163 days around Sep 29, 2023. Afterward, it decreases to 142 days by Dec 31, 2024, before rising again and stabilizing in the range of 150 to 155 days. This pattern aligns with the trends in inventory and receivables, indicating that fluctuations in inventory management are the dominant factor influencing the overall cycle duration.

Overall, the data indicates that while the receivable collection period remains relatively stable with slight improvements, the average inventory processing period is more variable and predominantly drives changes in the operating cycle. Periods of increased inventory days likely reflect challenges or strategic decisions in inventory management. The return to lower inventory days toward the end of 2024 suggests corrective actions may have been implemented to optimize working capital efficiency.


Average Payables Payment Period

Danaher Corp., average payables payment period calculation (quarterly data)

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


Payables Turnover Ratio
The payables turnover ratio demonstrates fluctuations over the analyzed periods. It initially decreased from 5.29 to 4.48 between April 2021 and December 2021, indicating a slowdown in the rate at which payables were being settled. Subsequently, the ratio generally increased, reaching a peak of 6.04 in September 2024. This upward trend suggests an improvement in the efficiency of accounts payable management, with payables being settled more rapidly in the later periods. However, slight declines and variability are observed in some quarters, reflecting some inconsistency in payment practices.
Average Payables Payment Period
The average payables payment period, which is inversely related to the payables turnover ratio, exhibited a contrasting pattern. It increased from 69 days in April 2021 to a high of 82 days by December 2021, signaling a longer duration taken to settle payables during this timeframe. Following this peak, there was a progressive reduction in the payment period, reaching a low of 60 days by September 2024. This trend aligns with the increasing payables turnover ratio, indicating an acceleration in payment settlements. The payment period shows minor fluctuations toward the end of the dataset but remains generally lower compared to the initial periods, reflecting improved payment efficiency.
Overall Observations
Over the analyzed periods, the company improved its payables management, as evidenced by the increasing payables turnover ratio and decreasing average payment period after late 2021. The transitional period of extended payment times around late 2021 may have been influenced by operational or strategic factors but was followed by a clear enhancement in payment promptness. The consistency in the later periods suggests stabilization in payment practices at a relatively efficient level.

Cash Conversion Cycle

Danaher Corp., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).

1 Q3 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The analysis of the quarterly financial metrics reveals notable trends in the company’s working capital management, particularly in its inventory, receivables, payables, and overall cash conversion cycle.

Average Inventory Processing Period
This metric shows a somewhat fluctuating pattern over the observed quarters. Starting at 84 days in early 2021, it peaked several times, reaching as high as 104 days in the first quarter of 2023. Although there is a tendency for periodic declines, the overall trend suggests a lengthening in the inventory processing time, implying slower inventory turnover or increased stock holding periods during certain intervals. The period decreased notably to 88 days in late 2024, indicating a potential improvement in inventory management toward the end of the period.
Average Receivable Collection Period
The receivable collection period remains relatively stable with minor fluctuations. The values generally oscillate between the low 50s and 60 days. It started at 58 days and showed a decrease around early 2022 reaching lows near 51-52 days, suggesting improved collection efficiency in that timeframe. However, it slightly rose again near the 60-day mark in late 2022 before once more stabilizing in the low 50s through mid-2024. This stability indicates consistent credit and collection policies with only modest variances in customer payment behavior.
Average Payables Payment Period
The payables payment period exhibits more variability without a clear unidirectional trend. Early 2021 levels hovered around the high 60s to low 70s, peaked at 82 days by the end of 2021, indicating extended payment terms or delayed payments to suppliers. Subsequently, this period generally trended downward from 2022 through 2024, dropping to values near 60 days, with slight rises in some quarters. The shortening of payables days in the latter period may reflect improved payment discipline or renegotiated supplier terms.
Cash Conversion Cycle (CCC)
The cash conversion cycle displays significant fluctuations over the examined period. Initially stable in the mid-70s days range during 2021, it declined sharply to 63 days at year-end 2021, which indicates enhanced operating efficiency and quicker conversion of resources into cash. However, throughout 2022 and into early 2023, the CCC increased substantially, peaking near 98 days, reflecting slower cash recovery tied to inventory buildup or extended receivables. Post first quarter of 2023, a gradual recovery is apparent with the CCC trending downward to around 76 days by late 2024. Despite this, slight increases followed, indicating ongoing volatility in working capital management efficiency.